Molidustat for Japanese Patients With Renal Anemia Receiving Dialysis.

Akizawa, Tadao; Yamada, Takashi; Nobori, Kiyoshi; Matsuda, Yoshimi; Hayashi, Yasuhiro; Hayasaki, Takanori; Yamamoto, Hiroyasu

Akizawa, Tadao; Yamada, Takashi; Nobori, Kiyoshi; Matsuda, Yoshimi; Hayashi, Yasuhiro; Hayasaki, Takanori; Yamamoto, Hiroyasu.

Afiliación

Akizawa T; Division of Nephrology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan.
Yamada T; Research and Development Japan, Bayer Yakuhin, Ltd., Osaka, Japan.
Nobori K; Research and Development Japan, Bayer Yakuhin, Ltd., Osaka, Japan.
Matsuda Y; Research and Development Japan, Bayer Yakuhin, Ltd., Osaka, Japan.
Hayashi Y; Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd., Osaka, Japan.
Hayasaki T; Medical Affairs and Pharmacovigilance, Bayer Yakuhin, Ltd., Osaka, Japan.
Yamamoto H; Division of Nephrology and Hypertension, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan.

Kidney Int Rep ; 6(10): 2604-2616, 2021 Oct.

Article en En | MEDLINE | ID: mdl-34622100

Palabras clave

darbepoetin alfa; dialysis; erythropoiesis-stimulating agent; hypoxia-inducible factor prolyl hydroxylase inhibitor; molidustat; renal anemia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Clinical_trials Idioma: En Revista: Kidney Int Rep Año: 2021 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google